The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives
Date
2019Author
Doubek, Michael
Greul, Rosemarie
Yavuz, Akif
Mattsson, Mattias
Hagglund, Hans
Panse, Jens
Sabato, Vito
Aberer, Elisabeth
Al-Ali, Haifa Kathrin
Morren, Marie-Anne
Varkonyi, Judit
Zink, Alexander
Niedoszytko, Marek
Lange, Magdalena
Zanotti, Roberta
van Anrooij, Bjorn
Bonifacio, Massimiliano
Bonadonna, Patrizia
Gleixner, Karoline V.
Hadzijusufovic, Emir
Perkins, Cecelia
Hartmann, Karin
Illerhaus, Anja
Merante, Serena
Elena, Chiara
Shoumariyeh, Khalid
von Bubnoff, Nikolas
Parente, Roberta
Triggiani, Massimo
Schwaab, Juliana
Jawhar, Mohamad
Caroppo, Francesca
Fortina, Anna Belloni
Brockow, Knut
Niederwieser, Dietger
Malcovati, Luca
Reiter, Andreas
Kennedy, Vanessa
Gotlib, Jason
Lortholary, Olivier
Hermine, Olivier
Arock, Michel
Kluin-Nelemans, Hanneke
Sperr, Wolfgang R.
Fuchs, David
Valent, Peter
Elberink, Joanna N. G. Oude
Gorska, Aleksandra
Metadata
Show full item recordAbstract
Mastocytosis is a unique hematologic neoplasm with complex biology and pathology and a variable clinical course. The disease can essentially be divided into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). In adults, SM is diagnosed in most cases and manifests as either indolent or advanced disease. Patients with advanced SM have an unfavorable prognosis with reduced survival. However, so far, little is known about the prevalence of various categories of SM and about prognostic factors. In an attempt to learn more about the behavior and evolution of various forms of CM and SM, the European Competence Network on Mastocytosis (ECNM) initiated a mastocytosis registry in 2012. In this article, the set up and start phase of this registry are described. Until 2018, more than 3000 patients from 12 countries and 25 centers have been enrolled. In a majority of all patients, robust follow-up data and relevant clinical end points are available. Using this data set, a series of registry projects have been launched, with the aim to validate previously identified diagnostic and prognostic variables and to identify new disease-related and patient-related parameters in various forms of mastocytosis. Moreover, the core data set of the registry will be useful to establish multiparametric scoring systems through which prognostication and individualized management of patients with mastocytosis should improve in the foreseeable future. (C) 2019 American Academy of Allergy, Asthma & Immunology
Collections
- Makale [92796]